According to Catalent's latest financial reports the company has a price-to-book ratio of 2.73.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 2.20 | 33.49% |
2022-12-31 | 1.65 | -67.76% |
2021-12-31 | 5.11 | 13.82% |
2020-12-31 | 4.49 | 26.62% |
2019-12-31 | 3.55 | 22.15% |
2018-12-31 | 2.91 | -46.48% |
2017-12-31 | 5.43 | -5.1% |
2016-12-31 | 5.72 | 11.47% |
2015-12-31 | 5.13 | -26.8% |
2014-12-31 | 7.01 | |
2013-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Supernus Pharmaceuticals
SUPN | 1.71 | -37.19% | ๐บ๐ธ USA |
Jazz Pharmaceuticals JAZZ | 1.87 | -31.44% | ๐ฎ๐ช Ireland |
Intercept Pharmaceuticals
ICPT | 11.1 | 305.22% | ๐บ๐ธ USA |